Antidepressant drug fluvoxamine may reduce COVID hospitalisation risk by one-third, finds study

Fluvoxamine, which is currently used to treat mental health conditions, was chosen for study as a potential treatment for COVID-19 due to its anti-inflammatory properties.

Related Keywords

Canada ,Brazil ,Brazilian ,Otavio Berwanger ,Angela Reiersen ,Professor At Washington University ,Mcmaster University ,Lancet Global Health ,World Health Organisation ,Associate Professor ,Washington University ,Edward Mills ,Essential Medicines ,Academic Research Organisation ,Hospital Israelita Albert Einstein ,Antidepressant ,Fluvoxamine ,Covid 19 ,Covid Hospitalisation ,Covid 19 Treatment ,Educe Covid Hospitalisation Risk ,